

TABLE OF CONTENTS

November 9, 2009

No. 2163

BUSINESS

- 1 Medipal Aims at Sales of ¥30 Bil. in China in FY2012
- 2 Takeda to Develop Global Business as “Medium-Sized Global Pharma”: Mr Hasegawa
- 3 Japan Is the Most Important Market in Asia: Mr Barr of Covance
- 4 Astellas Licenses MDV3100 for Prostate Cancer from Medivation
- 4 Half-Year Business Results of Major Domestic Companies
- 9 **BUSINESS NEWS IN BRIEF**
 - Eisai Opens Regional Office in Bahrain

MEDICAL DEVICES

- 8 Pharm. Business Will Continue to Growth: Mr Ludwig of BD
- 8 Terumo to Increase Focus on Relief of Cancer Pain
- 9 Eiken Chemical Launches Reagents for New-Type Influenza Virus
- 9 **Seminar**
 - Osteoporosis Treatment Effective for Glycemic Control: Prof. Sugimoto

GENERICS

- 10 Generic Amlodipine Comparable to Original Version: NPO Report
- 10 Generics' Share Lowest in Japan among 15 Advanced Countries

REGULATORY

- 11 Cravit's Patent Extension Rejected by IP High Court
- 11 Daiichi Sankyo Applies for Injectable Levofloxacin on the Same Day as IP High Court Ruling
- 12 *Chuikyo* Back to Work
 - Market Price Survey Finished, Results to Become Available in Mid-Nov.
- 13 Dr Adachi Confirms Conservative Stance toward Industry Proposal
- 13 Japan Is Obligated to Promote Use of Generics: Dr Suzuki
- 14 *Koroshio* Considers Extension of Tax Break on Research Expenses
- 14 PMDA Needs 2,000-3,000 Staff Members for Simultaneous Approval with US, EU: Chief Executive Kondo
- 15 3 Societies Call For Vaccination of Girls Aged 11-14 with Cervarix
 - Vaccination for Women Aged 11-14 Should Be Free of Charge
- 16 **REGULATORY NEWS IN BRIEF**
 - SymBio Submits NDA for SyB L-0501

- Abbott Japan, Eisai Apply for AS as Additional Indication for Humira
- Telavancin Submitted to EMEA: Asatellas, Theravance
- Herceptin Applied for HER2-Positive Gastric Cancer in Europe: Roche
- Cervical Cancer Vaccine Cervarix Approved in the US: GSK
- FDA Approves Use of Gardasil to Prevent Condyloma Acuminatum
- GSK's Votrient Approved by FDA for Advanced RCC
- Micardis Approved by FDA for CV Risk Reduction: BI
- Cimzia Approved by EU for RA
- Prolonged-Release Pramipexole Formulation Approved in EU

R&D

- 18 Eisai Ties Up with Quintiles to Develop Anti-cancer Drug Candidates
- 18 AZ to Apply for Vandetanib within 2009
- 19 JAPhMed Calls For Increases in Transparency in Research Donations
- 19 *Koroshio* Invites Applications for Designation as “Global Clinical Research Centers”
- 20 **R&D NEWS IN BRIEF**
 - Toyama Chemical Begins PIII for Antiviral Drug T-705
 - Celsion, Yakult Honsha Enroll First Japanese Patient in Global PIII ThermoDox Trial
 - Sanofi-aventis Completes Patients Enrollment for ALOHA Study
 - Sosei Assigns SD281 to Biocopea
 - Actemra + MTX Inhibit Joint Destruction Compared to MTX Alone: Roche
 - NovoMix 30 Significantly Reduces HbA1c Compared to Insulin Glargine
 - Taxotere + Cisplatin + 5-FU Combination Extends OS in Advanced HNC: sanofi-aventis
 - Erbitux Significantly Increases OS in 1st-Line mCRC: Merck
 - Researchers from NIBO Identify LRG as New Biomarker
 - MORE Medical Ties Up with Australian CROs

SELF-MEDICATION

- 22 Kenko.com to Sell OTC Drugs On-line From Singapore
- 22 OTC Drugs Market Down 1% to ¥774 Bil. in 2008: Yano Research
- 23 Nissui to Launch OTC Version of Epadel in Spring 2010

MEDICAL FACILITIES & NURSING CARE

- 23 Stroke Policy Summit Stresses the Need for Law